CA2173387A1 - A process for the preparation of a liposomal, in water dispersive, orally administerable, solid, dry therapeutic formulation - Google Patents

A process for the preparation of a liposomal, in water dispersive, orally administerable, solid, dry therapeutic formulation

Info

Publication number
CA2173387A1
CA2173387A1 CA2173387A CA2173387A CA2173387A1 CA 2173387 A1 CA2173387 A1 CA 2173387A1 CA 2173387 A CA2173387 A CA 2173387A CA 2173387 A CA2173387 A CA 2173387A CA 2173387 A1 CA2173387 A1 CA 2173387A1
Authority
CA
Canada
Prior art keywords
solid
liposomal
preparation
therapeutic formulation
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2173387A
Other languages
French (fr)
Other versions
CA2173387C (en
Inventor
Giovanni Mazzei
Paolo Crivelli
Michele Muller
Fabrizio Marazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerbios Pharma SA
Original Assignee
Cerbios Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerbios Pharma SA filed Critical Cerbios Pharma SA
Publication of CA2173387A1 publication Critical patent/CA2173387A1/en
Application granted granted Critical
Publication of CA2173387C publication Critical patent/CA2173387C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The inventive process for the preparation of a liposomal, in water dispersive, orally administerable, solid, dry therapeutic formulation, is characterized in that - in a first step at least one biological ac-tive, lipophilic active component, at least one lipid, which forms vesicles, and at least one component, which stabilizes the vesicle structure and/or serves as solu-bilizer, are dissolved in at least one organic solvent, then - in a second step from the obtained homoge-neous solution the organic solvent(s) is (are) removed, then - in a third step the so obtained homogeneous mixture is hydrated, then - in a fourth step the so obtained suspension is treated mechanically during such a long time, until said active component is contained completely and homo-geneous distributed in the formed liposomal particles, then - in a fifth step the water is removed by means of spray drying or by means of a granulating pro-cess and the so obtained solid, which has the form of a powder or of granules, is obtained.
CA002173387A 1995-04-03 1996-04-03 A process for the preparation of a liposomal, in water dispersive, orally administerable, solid, dry therapeutic formulation Expired - Fee Related CA2173387C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH00923/95-2 1995-04-03
CH00923/95A CH689139A5 (en) 1995-04-03 1995-04-03 Process for the preparation of a liposomal, in water dispersable, orally administrable, solid, dry therapeutic formulation.

Publications (2)

Publication Number Publication Date
CA2173387A1 true CA2173387A1 (en) 1996-10-04
CA2173387C CA2173387C (en) 2000-02-01

Family

ID=4198316

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002173387A Expired - Fee Related CA2173387C (en) 1995-04-03 1996-04-03 A process for the preparation of a liposomal, in water dispersive, orally administerable, solid, dry therapeutic formulation

Country Status (6)

Country Link
EP (1) EP0736299B1 (en)
JP (1) JP2911814B2 (en)
CA (1) CA2173387C (en)
CH (1) CH689139A5 (en)
DE (1) DE59608169D1 (en)
ES (1) ES2165936T3 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
US6824790B2 (en) 2002-01-09 2004-11-30 Enzrel Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
DE10205362A1 (en) * 2002-02-08 2003-08-21 Abbott Gmbh & Co Kg Process for the preparation of water-dispersible dry powder of water-poorly soluble compounds
US20060093661A1 (en) 2002-05-07 2006-05-04 Kapac, Llc Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
US20030212046A1 (en) * 2002-05-07 2003-11-13 Kapac, Llc Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US9205094B2 (en) 2006-12-22 2015-12-08 Ironwood Pharmaceuticals, Inc. Compositions comprising bile acid sequestrants for treating esophageal disorders
ATE544759T1 (en) 2007-07-21 2012-02-15 Albany Molecular Res Inc 5-PYRIDINONE-SUBSTITUTED INDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF
CA2722611A1 (en) 2007-11-21 2009-05-28 Decode Genetics Ehf Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
CA2727055C (en) 2008-01-11 2016-12-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
WO2010084499A2 (en) 2009-01-26 2010-07-29 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
SG177523A1 (en) 2009-07-14 2012-02-28 Albany Molecular Res Inc 5-ht3 receptor modulators, methods of making, and use thereof
AR078950A1 (en) 2009-11-09 2011-12-14 Ironwood Pharmaceuticals Inc PEPTIDE AGONIST OF GUANILATE CYCLASE C (GC-C) USEFUL FOR TREATMENTS OF GASTROINTESTINAL DISORDERS
RU2012128509A (en) 2009-12-07 2014-01-20 Айронвуд Фармасьютикалз, Инк. METHODS FOR TREATING DISEASES OF THE GASTROINTESTINAL TRACT
EP2506805A1 (en) 2010-01-25 2012-10-10 Alcon Research, Ltd. Intraocular meniscus lens providing pseudo-accommodation
EP2536742B1 (en) 2010-02-17 2017-07-19 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9303066B2 (en) 2011-05-11 2016-04-05 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012155101A1 (en) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9527887B2 (en) 2011-06-08 2016-12-27 Ironwood Pharmaceutical, Inc. Treatments for gastrointestinal disorders
US9617305B2 (en) 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
HUE032237T2 (en) 2011-08-17 2017-09-28 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
PT3288578T (en) 2015-05-01 2023-03-28 Ironwood Pharmaceuticals Inc Compositions for colon cleansing and the treatment of gastrointestinal disorders
CA3093340A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CA3124700A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
HRP20221361T1 (en) 2020-05-18 2023-01-06 Orexo Ab New pharmaceutical composition for drug delivery
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
KR20240103005A (en) 2021-11-25 2024-07-03 오렉쏘 에이비 Pharmaceutical composition containing adrenaline
DE202023001978U1 (en) 2023-09-20 2023-09-29 Penta Phi Eg Formulation comprising Coenzyme Q10 and creatine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL28272A (en) * 1967-07-07 1970-12-24 Menachemoff E Emulsifiable powder containing 3,5-dinitro-o-toluic-acid amide(d.o.t.)
JPS5770814A (en) * 1980-10-17 1982-05-01 Isamu Horikoshi Oral preparation of blood clotting eighth factor
FR2521565B1 (en) * 1982-02-17 1985-07-05 Dior Sa Parfums Christian PULVERULENT MIXTURE OF LIPID COMPONENTS AND HYDROPHOBIC CONSTITUENTS, METHOD FOR PREPARING SAME, HYDRATED LIPID LAMELLAR PHASES AND MANUFACTURING METHOD, PHARMACEUTICAL OR COSMETIC COMPOSITIONS COMPRISING HYDRATED LAMID PHASES
SE8403905D0 (en) * 1984-07-30 1984-07-30 Draco Ab LIPOSOMES AND STEROID ESTERS
CA1321351C (en) * 1987-02-23 1993-08-17 Helmut Otmar Hauser Method of dehydrating vesicle preparations for long-term storage
JP2501336B2 (en) * 1987-07-02 1996-05-29 第一製薬株式会社 Stable liposomal formulation
US4963362A (en) * 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
JP3148769B2 (en) * 1992-01-14 2001-03-26 エーザイ株式会社 Pro-nanosphere and its manufacturing method

Also Published As

Publication number Publication date
EP0736299A1 (en) 1996-10-09
CA2173387C (en) 2000-02-01
JP2911814B2 (en) 1999-06-23
EP0736299B1 (en) 2001-11-14
CH689139A5 (en) 1998-10-30
DE59608169D1 (en) 2001-12-20
JPH0995438A (en) 1997-04-08
ES2165936T3 (en) 2002-04-01

Similar Documents

Publication Publication Date Title
CA2173387A1 (en) A process for the preparation of a liposomal, in water dispersive, orally administerable, solid, dry therapeutic formulation
CA2108288A1 (en) Liposomal cyclosporin formulation and process for the preparation thereof
NO175531C (en) Analogous Process for the Preparation of Therapeutically Active Imidazo (4,5-b) -quinolinyloxyalkanoic Acid Amides
HU903846D0 (en) Process for producing imidazolyl-alkenic acids and pharmaceutical preparatives containing these compounds as active substance
CA2304662A1 (en) Methods for fabricating polymer-based controlled release preparations
HUT43940A (en) Herbicides comprising sulfonyl urea derivatives as active substance and process for preparing the active substance
CA2245708A1 (en) Solid formulations containing trehalose
CA2235243A1 (en) Method and preparations for stabilizing biological materials by drying methods without freezing
CA2244767A1 (en) Process for the production of powdered pulmonary surfactant preparations
PT744941E (en) PROCESS FOR PREPARING PHARMACEUTICAL FORMULATIONS OF FINE PARTICLES
HUT45844A (en) Pesticides comprising imidazole derivatives as active ingredient and process for producing the active ingredients
HUT53634A (en) Herbicides comprising aromatic carboxylic acid derivatives as active ingredient and process for producing the active ingredients
NO307181B1 (en) Process for the preparation of N- [3 (3-cyanopyrazole [1,5-a] pyrimidin-7-yl) phenyl] -N-ethylacetamide
CA2216320A1 (en) Stable emulsions and dry powders of mixtures of fat-soluble vitamins, their preparation and use
PT973506E (en) METHOD FOR PREPARING FORMS OF SOLID PHARMACEUTICAL DOSAGE
FI961348A0 (en) Method for coating small droplets or nanometric particles
HUT46676A (en) Herbicides comprising 1h-imidazole derivatives as active ingredient and process for producing the active ingredients
HUT53363A (en) Process for producing new perhydroazacycloalkano(1,2-a)imidazole derivatives and pharmaceutical compositions comprising such compounds as active ingredient
HUT49875A (en) Herbicides comprising substituted sulfonylaminoazole derivatives as active ingredient and process for producing the active ingredients
PL317856A1 (en) Pharmaceutic preparation containing a hydrophobous active substance and an efffervescence producing system and method of obtaining such preparation
HUT45529A (en) Process for producing pyrazolo/3,4-d/pyrimidine derivatives and pharmaceutics comprising these compounds as active ingredient
HU9202358D0 (en) Imidazo(2,1-b)benzothiazole-3-acetamide derivatives, method for producing them and pharmaceutical preparatives containing said components as active agents
NO985787L (en) Process for the preparation of spherical particles of energetic compounds
HUT44764A (en) Process for producing new sulfonamidoethyl derivatives and pharmaceutical preparations comprising them as active substance
HUT53109A (en) Process for producing benzodiazepine derivatives and pharmaceutical compositions comprising such compounds as active ingredient

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20100406